266 related articles for article (PubMed ID: 36325577)
1. Translational alterations in pancreatic cancer: a central role for the integrated stress response.
Shin S; Solorzano J; Liauzun M; Pyronnet S; Bousquet C; Martineau Y
NAR Cancer; 2022 Dec; 4(4):zcac031. PubMed ID: 36325577
[TBL] [Abstract][Full Text] [Related]
2. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
Su CC
Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
[TBL] [Abstract][Full Text] [Related]
3. Targeting Protein Synthesis in Colorectal Cancer.
Schmidt S; Denk S; Wiegering A
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455578
[TBL] [Abstract][Full Text] [Related]
4. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway.
Pervin S; Singh R; Hernandez E; Wu G; Chaudhuri G
Cancer Res; 2007 Jan; 67(1):289-99. PubMed ID: 17210710
[TBL] [Abstract][Full Text] [Related]
6. The integrated stress response in cancer progression: a force for plasticity and resistance.
Lines CL; McGrath MJ; Dorwart T; Conn CS
Front Oncol; 2023; 13():1206561. PubMed ID: 37601686
[TBL] [Abstract][Full Text] [Related]
7. Translation initiation and its relevance in colorectal cancer.
Minnee E; Faller WJ
FEBS J; 2021 Dec; 288(23):6635-6651. PubMed ID: 33382175
[TBL] [Abstract][Full Text] [Related]
8. The two faces of the Integrated Stress Response in cancer progression and therapeutic strategies.
Licari E; Sánchez-Del-Campo L; Falletta P
Int J Biochem Cell Biol; 2021 Oct; 139():106059. PubMed ID: 34400318
[TBL] [Abstract][Full Text] [Related]
9. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.
Chappell WH; Steelman LS; Long JM; Kempf RC; Abrams SL; Franklin RA; Bäsecke J; Stivala F; Donia M; Fagone P; Malaponte G; Mazzarino MC; Nicoletti F; Libra M; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Laidler P; Milella M; Tafuri A; Bonati A; Evangelisti C; Cocco L; Martelli AM; McCubrey JA
Oncotarget; 2011 Mar; 2(3):135-64. PubMed ID: 21411864
[TBL] [Abstract][Full Text] [Related]
10. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
11. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
12. The integrated stress response in the induction of mutant KRAS lung carcinogenesis: Mechanistic insights and therapeutic implications.
Koromilas AE
Bioessays; 2022 Aug; 44(8):e2200026. PubMed ID: 35587163
[TBL] [Abstract][Full Text] [Related]
13. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
14. Upstream Open Reading Frames Differentially Regulate Gene-specific Translation in the Integrated Stress Response.
Young SK; Wek RC
J Biol Chem; 2016 Aug; 291(33):16927-35. PubMed ID: 27358398
[TBL] [Abstract][Full Text] [Related]
15. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
[TBL] [Abstract][Full Text] [Related]
16. Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors.
Gerson-Gurwitz A; Young NP; Goel VK; Eam B; Stumpf CR; Chen J; Fish S; Barrera M; Sung E; Staunton J; Chiang GG; Webster KR; Thompson PA
Front Oncol; 2021; 11():766298. PubMed ID: 34900714
[TBL] [Abstract][Full Text] [Related]
17. eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways.
Shahbazian D; Parsyan A; Petroulakis E; Hershey J; Sonenberg N
Cell Cycle; 2010 Oct; 9(20):4106-9. PubMed ID: 20948310
[TBL] [Abstract][Full Text] [Related]
18. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
Bibollet-Bahena O; Almazan G
J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
[TBL] [Abstract][Full Text] [Related]
19. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
20. The ever-evolving role of mTOR in translation.
Fonseca BD; Smith EM; Yelle N; Alain T; Bushell M; Pause A
Semin Cell Dev Biol; 2014 Dec; 36():102-12. PubMed ID: 25263010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
